The p2b dose ranging study in patients with osteoarthritis showed that higher exposure levels to APPA correlates with better pain reduction. This was particularly evident in patients with worse pain at the start of the study. These dose-dependent, consistent, and clinically relevant effects across all efficacy endpoints observed in subgroups with higher baseline pain level has strong PK/PD (Pharmacokinetics / Pharmacodynamics) association.
To unlock APPA’s full potential, we have developed and patented a liquid capsule formulation designed to significantly increase systemic exposure. We have planned a PK bridging study with the Liverpool Clinical Research Facility to confirm the greater bioavailability of the liquid formulation. That will be followed by a confirmatory Phase 2b/3 clinical study with leading OA CRO, NBCD in Denmark.
To the best of our knowledge, no competitor is actively developing an oral OA drug designed for chronic use.